Break free from Frequent Urination

COMPOSITION – Tamsulosin HCI IP 0.4mg + Dutasteride IP 0.5mg



Tamsulosin HCI 

Drug class: Alpha blockers

  • Tamsulosin with a low propensity for side effects, is relatively selective for α1A and D-adrenoceptors over α1B-adrenoceptors.
  • The long-term efficacy and safety of tamsulosin in BPH (benign prostatic hyperplasia), evident from previous shorter-term and 4-year long-term clinical trials are proven.
  • This α1A subtype selective adrenergic receptor blocker is a viable long-term alternative to surgery.


Drug class: 5-alpha reductase inhibitors

  • Dutasteride is the first dual inhibitor of both 5α reductase isoenzymes.
  • Improves urinary symptoms and flow rate.
  • Also associated with significant improvements in BPH Impact Index (BII) score, reflecting improvements in quality of life for men with BPH.
  • Advantageous in the chemoprevention of prostate cancer


  • Combination therapy with dutasteride and tamsulosin was significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression.
  • Combination therapy was significantly superior to tamsulosin monotherapy (but not dutasteride monotherapy) at reducing the relative risk of AUR (acute urinary retention) or BPH-related surgery.
  • Safety and tolerability of combination therapy was consistent with previous experience with dutasteride and tamsulosin monotherapies. 
  • Combined therapy with dutasteride plus tamsulosin provided better long-term (up to 4years) control of both storage and voiding LUTS compared with tamsulosin monotherapy.